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Background: The rationale for the English National Chlamydia Screening Programme (NCSP) has been questioned.
There has been little analysis, however, of what drove the NCSP’s establishment and how it was implemented. Such
analysis will help inform the future development of the NCSP. This study used a qualitative, theory-driven approach
to evaluate the rationale for the NCSP’s establishment and implementation.
Methods: Semi-structured interviews with 14 experts in chlamydia screening were undertaken. The interview data
were analysed with policy documents and commentaries from peer-reviewed journals (published 1996–2010) using
the Framework approach.
Results: Two themes drove the NCSP’s establishment and implementation. The first, chlamydia control, was
prominently referenced in documents and interviews. The second theme concerned the potential for chlamydia
screening to advance wider improvements in sexual health. In particular, screening was expected to promote sexual
health services in primary care and encourage discussion of sexual health with young people. While this theme was
only indirectly referenced in policy documents, it was cited by interviewees as a strong influence on
implementation in the early years. However, by full rollout of the Programme, a focus on screening volume may
have limited the NCSP’s capacity to improve broader aspects of sexual health.
Conclusions: A combination of explicit and implicit drivers underpinned the Programme’s establishment. This
combination may explain why there was widespread support for its introduction and why implementation of the
NCSP was inconsistent. The potential to improve young people’s sexual health more comprehensively should be
made explicit in future planning of the NCSP.Background
The National Chlamydia Screening Programme (NCSP)
was established in England in 2002 to “prevent and control
chlamydia through early detection and treatment of asymp-
tomatic infection; reduce onward transmission to sexual
partners; and prevent the consequences of untreated infec-
tion”. It has been available in all areas of England since
2008 and in 2009/2010 provided over 1.5 million tests to
young people [1].
When chlamydia screening was proposed in 1998 by an
Expert Advisory Group of the Chief Medical Officer, it was
expected to “produce considerable health gains” and “re-
duce health costs” by preventing reproductive ill health
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distribution, and reproduction in any mediumtubal factor subfertility) thought to be caused by chlamydia
infection [2]. Eleven years later, the National Audit Office
questioned whether it was worth investing “so much public
money” to tackle chlamydia when the evidence base for
screening was “subject to debate” [3]. While this and other
reports have criticised the NCSP [4], there has been little
objective analysis of the broader factors driving the Pro-
gramme’s establishment or exploration of decisions under-
lying its implementation. Such analysis is needed to inform
decisions about the NCSP’s future. It is important at this
time when extensive healthcare reforms underway across
the English National Health Service will challenge the
NCSP’s management and direction [5].
The NCSP is not unique in attracting controversy or
in being established on the basis of limited evidence: for
example, historical analysis of the cervical screening
programme illustrates a similarly optimistic initial re-
sponse, despite scant evidence, and later concerns aboutntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tions are often informed by plausible intuition rather
than evidence-based pathways describing anticipated
outcomes [7]. In some instances, such approaches are
grounded in theory but in many cases they are based on
implicit assumptions. It is helpful to distinguish between
these approaches in order to fully understand the moti-
vations for the establishment of new interventions and
to explain the effectiveness of widespread adoption and
dissemination of the intervention.
Aims and objectives
The aim of this study was to explore implicit and explicit
determinants of the establishment and implementation of
the English National Chlamydia Screening Programme to
inform the future of chlamydia control and sexual health
programmes for young people. The objectives were to:
– Track the scientific and policy context under which
the NCSP was first considered, established and
implemented;
– Make explicit any initial theory and assumptions
underlying the policy to introduce a national
chlamydia screening programme in England;
– Document changes in, and challenges to, these
drivers as the NCSP was implemented.
Methods
Approach
Theory-driven evaluation (TDE) encompasses a family of
approaches that first seeks to articulate the links between
what programme designers planned to do and what they
expected to attain. This requires making implicit assump-
tions explicit so they can be subject to critical appraisal and
identifying the full spectrum of possible impacts of the
intervention [8,9]. TDE then goes on to explain programme
outcomes in the light of any underlying theory identified,
other assumptions or motivating factors. This first stage of
understanding the intervention requires a qualitative ap-
proach. TDE acknowledges that interpretation of the
underlying theory or other drivers for the programme may
change as the programme is rolled out and is subject to fur-
ther scrutiny [10]. A recent TDE of a sexual health
programme provided the basis for translating a theory-
driven approach to address our aim [11].
In line with the principles of realistic evaluation (one
form of TDE), we sought evidence that would best illu-
minate the theory or other underlying drivers to the
NCSP when it was established and how these evolved
during implementation [12]. We therefore focused our
data collection on sources that would enable us to track
the context in which the NCSP was first considered and
later delivered and to track the thinking that under-
pinned the programme’s initiation and implementation.Data collection
We constructed a timeline tracking the scientific and
policy context from 1996 to 2010 using:
– published research (randomised controlled trials and
systematic reviews) on chlamydia screening
– English Department of Health documents
– NCSP strategy and annual reports
– Health Protection Agency surveillance data on
chlamydia diagnoses rates
To make explicit any initial theory underlying the pol-
icy to establish the NCSP and to document changes as
the NCSP was implemented, we used a combination of
interviews and documentary analysis:
– Interviews: we selected a purposive sample of 14
experts, chosen because of their integral involvement
in the NCSP’s establishment or implementation or
because of their role as independent academic
experts during the period 1996–2010. These
included; national policy makers (Department of
Health civil servants); people working within or
advising the national team responsible for
establishing the NCSP (e.g. members of the Chief
Medical Officer’s Expert Advisory Group into
Chlamydia trachomatis, NCSP Steering Group, the
Independent Sexual Health Advisory Group and the
National Screening Committee) and academics who
have published on chlamydia control in England.
The interviews, conducted by JS and PB from July
2010-Mar 2011 at UCL, in participants’ workplaces or
by telephone, followed a semi-structured format (topic
guide in supplementary material additional file 1),
were audio-recorded and transcribed. All of the
experts approached agreed to be interviewed and all
were aware of PB’s current role as medical adviser to
the NCSP.
– Policy documents: to examine the stated rationale for
key decisions, we searched the Department of Health
online publications library using the terms
“chlamydia” and “sexual health” for the period 1996–
2010. This generated 209 publications of which 45
were indirectly relevant to the NCSP and 18 had
direct relevance. One document (Research to inform
the national media campaign teenage pregnancy in
England (2000)) was not available electronically but
had no apparent relevance to the programme and so
was not examined.
– Commentaries: to understand contemporary
scientific and clinical opinion on chlamydia
screening, we searched the Web of Knowledge
database for commentaries and editorials published
in peer-reviewed journals 1996–2010 using the terms
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Citation values and published responses were used
as crude indicators of an article’s profile within the
clinical/scientific community. We selected articles
with relevance to chlamydia screening in England
that were cited at least five times and/or with
published responses. We identified 26 papers for
inclusion into our detailed analysis.
Analysis
We organised data from the interview transcripts, policy
documents and commentaries using the Framework
approach [13]. JS and PB developed a conceptual frame-
work and independently coded several transcripts to iden-
tify themes (theories, assumptions, ideas, context) of
relevance to the initiation and implementation of the
NCSP. For quality assurance, ten sources were independ-
ently coded by both JS and PB, areas of discordance dis-
cussed and the coding framework refined. We coded the
remaining transcripts, policy documents and articles to
identify the themes emerging most prominently. We sum-
marised all coded data sources into charts organised by
theme and stage of initiation and implementation. Quota-
tions from interviews and documents were selected that
encapsulated the themes described.
Ethical approval
We sought ethical approval for this study from UCL re-
search ethics committee. This study was considered exempt
from the requirement for ethical approval because the re-
search involved review of publicly available information
and interviews with individuals on their professional views
about chlamydia screening not personal information.
Results
Timeline of events
Political and strategic developments in the NCSP are
tracked against delivery and evidence for chlamydia
screening (Figure 1).
The decision to introduce chlamydia screening in England
(1996–2000)
In 1996, the Chief Medical Officer (CMO) convened an
Expert Advisory Group to formally consider the establish-
ment of a chlamydia screening programme in England. The
Group’s formation was in response to mounting interest in
chlamydia screening in the UK [14,15], and promising ob-
servational studies of screening in other countries [16,17].
At this time, the other scientific evidence to support the
effectiveness of chlamydia screening comprised one trial of
screening from the USA [18]. Data from genito-urinary
medicine (GUM) clinics across England showed increas-
ing diagnoses in young people although there were no
population-based estimates of chlamydia prevalence.In 1998, the CMO published a report which proposed the
introduction of chlamydia screening in England. It recom-
mended an opportunistic screening model, targeted towards
young women, delivered in general practice and community
sexual and reproductive health services. It also called for a
research programme including a randomised controlled
trial of screening in England. The NHS Health Technology
Assessment Programme subsequently commissioned cross-
sectional feasibility and acceptability studies [19]. The
Department of Health also funded a pilot of opportunistic
screening in two areas in 1999. These pilots – where GPs
were paid to offer tests - reported high uptake in primary
care (>50 %) and found over 10 % of young people tested
positive for chlamydia [20,21].
Establishment of the NCSP and rollout across the country
(2001–2010)
In 2001, the sexual health strategy for England 2001–
2011 was published. This strategy highlighted serious
problems in sexual health care, including four-week
waits for urgent appointments in GUM and patchy
provision outside specialist GUM services, with few GPs
providing sexual health care (health promotion, advice or
STI testing and treatment) other than contraception. It
presented a vision of sexual health as an integrated
programme, encompassing both contraception and STIs
(including HIV) and proposed a new model for deliver-
ing sexual health services, where provision was expanded
to primary care [22]. As part of this model, it proposed a
national screening programme based on the CMO’s 1998
delivery recommendations, to be implemented in phases,
with full rollout across England by 2008. Testing in
GUM clinics was not part of this programme. In 2004,
the Public Health White Paper accelerated the schedule,
promising national provision by 2007 and announced
funding to support implementation [23]. In the absence
of empirical studies, modelling data estimated the level
of coverage required to reduce prevalence [24]. National
targets for screening coverage were first announced in
2005. From 2007, local areas were monitored against
these targets.
The NCSP delivery model changed as the Programme
expanded. By 2003, the target population included men.
By 2004, testing was conducted outside of general prac-
tice and sexual health services in non-traditional settings
such as pubs, clubs, sporting events and festivals. Imple-
mentation did not occur as planned: national provision
was later than expected, numbers of people tested
remained low, particularly in primary care, which
accounted for less than 20 % of chlamydia test delivery,
and amongst men, who account for less than 40 % of
NCSP tests [25]. As a result, coverage targets were
missed by a significant margin in 2007/2008. After 2008,
chlamydia tests performed outside the NCSP (but not in
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Figure 1 NCSP timeline 1996–2010: context, strategy and delivery.
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were almost met [25].
From 2006, the validity of earlier trials was more thor-
oughly and widely questioned in systematic reviews,
prompting more empirical research outside England to
underpin screening policy [26,27]. In addition, researchers
have since given greater attention to the secular changes (eg
lower rates of partner change as a result of HIV prevention
messages in the 1990s) that may have explained the initial
fall in chlamydia diagnoses following the introduction of
screening programmes [28,29]. Evidence remained equivo-
cal: for example, in 2010 a trial in England of chlamydia
screening reported a non-significant benefit of screening for
reducing pelvic inflammatory disease [30]. This trial’s limita-
tions also illustrated the significant challenges of delivering
chlamydia screening even in a research context eg achieving
uptake of sufficient numbers of young people [31].
Underlying themes
Establishing the NCSP
We did not identify a consistent theoretical basis for the
NCSP. However, two underlying themes emerged that
underpinned the establishment and implementation of
the NCSP. We refer to the first theme as ‘explicit’ be-
cause it is central to the stated aims of the Programmeand the second theme as ‘implicit’ because it was not
stated in policy documents but emerged from interviews.
Theme 1: The first theme corresponds to the explicitly
stated aims of the NCSP, which are to reduce
chlamydia prevalence and sequelae, in response to
concerns about rising diagnoses (Figure 1, dark blue
boxes). Diagnosis was made possible by the advent of
new technology, which was highly sensitive to detecting
chlamydia and in contrast to older tests, was much less
invasive, often requiring a urine test only. As the
illustrative quotes below indicate, he importance of
advances in diagnostic technology for the introduction
of screening was corroborated by evidence from
interviews, and other contemporary documents.
The CMO’s report identified chlamydia as a public
health problem and screening as the policy response.
This position was widely supported by the scientific and
clinical community in England:
“The personal and economic costs of untreated genital
chlamydial infection are considerable.”
Johnson, BMJ, 1996 [15]
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documented: the disease may be implicated in as
much as 50 % of cases.”
Boag and Kelly, BMJ, 1999 [32]
“We’d been seeing chlamydia figures going up and up
and there was a growing awareness that it was a
major cause of pelvic inflammatory disease. . .. ectopic
pregnancy and I suppose to my mind the trigger for all
of this probably was the advent of molecular
diagnostics, the idea that actually you could undertake
testing using so-called non-invasive specimens.”
Interview, CMO Expert Advisory Group member
(1996–2001)
While the CMO’s report acknowledged that data on
prevalence of chlamydia sequelae were “incomplete” and
“uncertain”, its bold statements that sequelae were “severe”
and that management would result in “considerable health
benefit” [2] went largely unchallenged in subsequent com-
mentaries and letters, despite the lack of trial evidence
from England at that time and the incomplete knowledge
concerning the prevalence and natural history of chla-
mydia. Instead, discussions focused on the extent to which
screening would be acceptable to young people and how it
should be delivered. This is illustrated in the quotes below:
"The case for screening is made.”
Boag and Kelly, BMJ, 1999 [32]
“The Chief Medical Officer's plan for immediate action
on Chlamydia trachomatis. . .is a step in the right
direction, but it does not go far enough.”
Letter from Opaneye, BMJ, 1999 (in response to Boag
& Kelly editorial) [32]
“I was shocked when I looked back at it [the CMO’s
report]. And actually it doesn’t question whether there
should be a screening programme, the decision has
obviously been made and it’s just which target groups,
which tests.”
Interview, Independent academic expert (1996–2011)
“[A pilot of] opportunistic testing . . . achieved coverage
of under 30 % among its target population. . .If the low
response . . . is repeated in national pilot studies using
similar methodology then few individuals are likely to
achieve long term health benefits and community
transmission is unlikely to be greatly reduced.”Letter from Macleod et al, BMJ, 1999 (in response to
Boag and Kelly editorial) [32]
“[The NHS pilots aimed to find out] how feasible was
it to ask people to pee in a pot [i.e. do a urine test]. . .
for an STI they hadn’t actually gone along to ask
about in the first place.”
Interview, NCSP Steering Group member (1999–2008)
Theme 2: A second theme also emerged from the
interviews (Figure 1, light blue boxes). It was not
referenced in policy documents, and we therefore refer to
it as an implicit theme. This was concerned with the
contribution of chlamydia screening to advancing wider
sexual health service delivery. As described in the timeline
and in interviews, sexual health services in the late 1990s/
early 2000s were in urgent need of serious investment:
“It was all part of a growing dissatisfaction with a
resurgence in STDs. There were real concerns about
access to clinical services, under capacity in GUM
clinics waiting times, you know that was part of the
narrative that had its origins in the late 1990s.”
Interview, NCSP Steering Group member (2000–2004)
Rising chlamydia diagnoses were quoted by intervie-
wees and widely in policy documents to support claims
of increasing burden of sexual ill-health:
“England is currently witnessing a rapid decline in its
sexual health. Around one in ten sexually active young
women (and many men) are infected with chlamydia.
Syphilis rates have increased by 500 % in the last six
years and those for gonorrhoea have doubled. Rates of
teenage pregnancy are the highest in Europe. Sexual
dysfunction is a largely silent problem within society.
Sexual health services appear ill-equipped to deal with
the crisis that confronts them.”
Third report of session 2002–03 on sexual health,
House of Commons Health Committee, 2003 [33]
As shown in the timeline and corroborated in the
interview data, in contrast to the previous decade, sig-
nificant efforts were now successful in gaining political
recognition of this problem:
“At that point to put sexual health into a historical
context, it was very much seen as the Cinderella
service of all services right across the board. . .. We had
the first ever national strategy on sexual health and
that had taken 18 months or so to do.”
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member (2002–2011)
Chlamydia screening was recognised as a vehicle to
engage young people in discussions about their sexual
health and an opportunity to drive increased access to
services for management of STIs (white dotted-line box,
Figure 2). This was evident from interviews and from
an article by those leading the first English screening
pilots:
“The proposed screening programme would demand
changes in clinical practice and closer alliances
between health services. This provides an opportunity
for new partnerships to be formed and facilitates a
more integrated approach to health care. In many
ways, it heralds the approach that is required to
manage the wide variety of sexual health issues that
confront us today.”
Pimenta et al, BMJ, 2000 [34]
“[Chlamydia screening was] an opportunity for
driving up sexual health care, sexual health
consultations.”
Interview, CMO Advisory Expert Advisory Group
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Figure 2 Themes underpinning the establishment and implementatioSpecifically, implementing a programme of chlamydia
screening was expected to expand sexual healthcare in
primary care and contraceptive services:
“It was clear that what we were setting up was not just
any proof of concept but a true opportunity to get
STDs out of the GUM sector and into the mainstream
of health protection in England.”
Interview, NCSP Steering Group member (2000–2004)
“From a service delivery point of view we did also see
this not only as increasing chlamydia testing and the
effects on chlamydia, but also to improve access to
sexual reproductive health services. If we could get
more of the right people through the Screening
Programme, it could have a positive effect on sexual
reproductive health services.”
Interview, National policy maker (2000–2005)
Although the Government frequently refers to chla-
mydia screening as part of its service reforms, neither
expanding access to sexual health care nor engaging
young people in sexual health were stated aims of the
NCSP. Similarly, this theme does not feature in the
CMO’s report [2], despite interview evidence that it was
discussed within the Expert Advisory Group:ning
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about and to open up that dialogue in sexual health
matters in a broader sense so there was definitely
discussion about that in the CMO group.”
Interview, CMO Advisory Expert Advisory Group
member (1996–1998)
“What one person [in the CMO’s group] said to me
was, ‘we see this Programme as being about the de-
stigmatisation of sexual health services’.”
Interview, National Screening Committee member
(1996–2007)
The aspiration to use screening in order to expand
community sexual health services and to promote dis-
cussion of sexual health with young people therefore
appears as an important, but largely implicit, influencing
factor in establishing the NCSP.
Our analysis also suggests however, that this implicit
theme influenced key implementation decisions. These
decisions included men’s eligibility for screening, where
there is little empirical evidence to guide decisions; most
published randomised controlled trials (RCTs) have been
conducted on women [18,30]. The CMO’s Expert Advis-
ory Group report (1998) initially recommended that
screening should focus on women only. This proposal
was adopted in the first phases of implementation. The
CMO’s recommendation was based partly on considera-
tions of feasibility, recognising that women are “are more
likely to attend health care settings” [35]. However, the
NCSP policy changed since the initial phases to recom-
mend that programmes should screen men and women
equally [36]. This was partly because studies conducted
since the CMO’s report found chlamydia prevalence was
similar in men and women [37,38]. However, there was
still no evidence that including men in the target popula-
tion for the NCSP would be cost effective in preventing
chlamydia-related harms. Our interviews and documen-
tary evidence suggest that the policy change was based
less on the potential to control chlamydia, and more to
promote equitable engagement of men in sexual health:
“[Screening men would] . . .give health professionals
and researchers the opportunity systematically to
investigate and address men's understanding of their
sexuality and sexual behaviour.”
Duncan and Hart, BMJ, 1999 [39]
“There was not robust evidence to say – when the
decision was made –that screening men would be cost-
effective.”Interview, NCSP Steering Group member (2000–2004)
“There was concern we were focusing chlamydia
screening efforts only on women and really missing an
opportunity in engaging men in sexual health.”
Interview, NCSP Steering Group member (2002–2005)
“[A focus on women only] ignored the (albeit small)
long-term health risks to men and, by placing the focus
on women, seemed unfairly to place the entire
responsibility on women too.”
Men’s Health Forum, 2005 [40]
Roll out of the Programme
The two themes evolved during implementation of the
NCSP.
Theme 1: Following rollout across the country, the gaps
in the evidence base to justify screening were now more
widely recognised. Flaws in early RCTs and questions
about the effectiveness of screening to control
chlamydia and prevent reproductive ill-health led to
questions about the “alacrity” with which “influential
groups have adopted chlamydia screening” [41]. As the
quote below shows, he gaps in the evidence
surrounding the natural history of chlamydia became a
central question for researchers.
“What I think we really need to know is what the natural
history of chlamydia is. We just simply don’t know what
we’re dealing with and on what scale and if you don’t
know that you can’t know whether your benefits are going
to outweigh your harms. It’s not enough to say you have
some case control studies to say that pelvic inflammatory
disease is associated with chlamydia or ectopic pregnancy
is associated with chlamydia.”
Interview, Independent academic expert (1999–2011)
These questions also led to questions about the policy
of funding chlamydia screening in England:
“. . ..the Department does not know how often infection
leads to serious health problems and hence whether it
is cost-effective to invest so much public money in
tackling this problem.”
National Audit Office, 2009 [3]
Theme 2: The focus of the NCSP’s monitoring was
entirely on delivery of testing and managing infections
so any wider effects were not formally captured.
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implementation, the NCSP drove integration of services
to some extent and did contribute to expanding sexual
healthcare delivery beyond specialist services:
“Even people who are critics of it [the NCSP] would
say it’s done more to bring together, force people to talk
to each other, to work together. . . I think without the
driver of the Programme, we wouldn’t have seen it to
the extent it has happened.”
Interview, National policy maker (2001–2010)
There was some evidence that providers in new ser-
vices used chlamydia screening as an opportunity to dis-
cuss sexual health with young people outside services.
“I do think above everything else it[offering chlamydia
screening] gives the opportunity to engage in a
conversation about sexual health which we’ve not been
able to do before.”
Interview, Local implementer (2008–2011)
As the Programme expanded, pressure to achieve high
coverage led to new services focusing solely on chlamydia
testing. These services became divorced from mainstream
care and offered little opportunity for sexual health pro-
motion [3]. The National Audit Office reported in 2009
that 40 % of young people tested within the NCSP by did
not receive sexual health advice.
“I don’t think the intention was ever that we would set
up a programme separate and different from other
aspects of sexual health locally, but unfortunately
that’s what seems to have evolved.”
Interview, National policy maker (2001–2010)
“I’m still going to areas where they are missing a trick,
that the chlamydia programme and the chlamydia
staff, they’ve got a huge role to play in the teenage
pregnancy agenda. It’s part of sexual health. You know,
it was very much put in its own little silo and even
though we wanted it to be a sustainable programme.”
Interview, National policy maker (2002–2005)
“The targets take away from what we’re doing
sometimes; it’s very hard for people offering screening
not to feel targets are all we care about.”
Interview, Local implementer (2008–2011)In addition, our interviews reflect the conflict between
achieving testing volumes and providing integrated sex-
ual health care through chlamydia screening. The follow-
ing two quotes come from two people involved during a
similar period of the NCSP’s development, both working
to implement the NCSP at a national level. These show
that some of those involved in implementing the NCSP
at a national level stated it was unacceptable for health
professionals to avoid discussing sexual health with
young people. However, others minimised the input
required from health professionals:
“It still amazes me, last week, I was . . . hearing from
the contraception service that . . . our ladies don’t come
here to talk about sex and sexually transmitted
infections. As far as I’m concerned that’s medically
negligent.”
Interview, National policy maker (2002–2005)
“The amount of time that GPs need to spend directly
talking about sex with their clients is zero frankly, they
may have to say have you been screened for chlamydia
this year . . .. . . and if the patient said no, give them a
leaflet.”
Interview, National implementer Implementer (2001–
2004)
Discussion
Key findings
We identified two concurrent themes that drove estab-
lishment of the NCSP. The first (explicitly stated in the
aims of the Programme) centred on the goal to control
chlamydia. The second theme (clearly articulated in
interviews, but not explicitly stated in policy) was the as-
piration to use chlamydia screening as a tool to achieve
wider improvements in young people’s sexual health and
service delivery.
Strengths and weaknesses of the analysis
Theory-driven evaluation approaches are commonly ap-
plied for social programmes but rarely used for health-
care interventions [11]. We found that analysis of the
theory underpinning a complex intervention was feasible
for a public health programme and generated results dir-
ectly useful to policy makers within a short time frame.
Two of the study authors (PB and JS) have been
involved in chlamydia screening (PB as NCSP medical
adviser and JS in evaluating the Programme) and have
published on the Programme [32,42]. This position as
'insider' researchers meant that both had knowledge of
and opinions on the subjects discussed in interviews.
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stages of the analysis and input from other study
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This evaluation occurred several years after the estab-
lishment of the NCSP. Therefore, memories of events
amongst our interviewees may be inaccurate/ incom-
plete. In particular, it is possible that our interviewees
consciously or unconsciously adopted a revisionist pos-
ition on this subject to justify what may now be per-
ceived as an unpopular position. To address this, we
tried wherever possible to seek documentary evidence to
triangulate the descriptions of events in our interviews.
In particular, we examined whether the implicit goal to
"improve sexual health" was only a post-hoc justification.
As evident from the illustrative quotes, the goal of im-
proving sexual health through transforming services was
referenced in documentation from 2000. Therefore, even
if interviewees selectively recalled this rationale more
strongly many years after the Programme was first
planned, there was evidence that it existed as a rationale
contemporaneously as well.
Other related studies
The limitations in the evidence base that existed when the
NCSP was established has been referred to elsewhere [4].
Our analysis builds on this literature by providing an ex-
planation for why chlamydia screening received such wide-
spread support despite the lack of conclusive experimental
evidence underpinning the NCSP. Policy makers, clinicians
and researchers recognised that chlamydia screening could
be used to expand sexual health beyond specialist services
and engage young people in sexual health.
The delivery of the NCSP has been subject to other crit-
ical reflection, most recently from the National Audit
Office (2009) and the Parliamentary Public Accounts
Committee (2010) [3,43]. These reports focused on the
NCSP’s failure to reach coverage targets. They concluded
that resources had been poorly used, due to “the difficul-
ties which can arise when a national initiative is introduced
into a locally-managed NHS” [3, p7]. The National Audit
Office recommended that criteria for the success of the
Programme should be defined. Our analysis provides an
argument to consider broadening the criteria for evaluat-
ing the Programme in addition to the measures of cover-
age and diagnoses rates. Possibilities could include
measuring the proportion of tests performed outside of
specialist services and the number of young people who
discussed sexual health matters during screening.
Conclusions
Our analysis of the origins of the NCSP indicated that
those involved in its establishment and implementationsought to achieve more than just chlamydia control.
There were implicit aspirations to use chlamydia screen-
ing to expand sexual health services in the community
and to engage young people in sexual health care. Our
interviews suggest that expansion of service delivery be-
yond specialist GUM services has been achieved. How-
ever, this was sometimes without expected gains in
service integration and did not always open a dialogue
into sexual health with young people.
NHS reforms may significantly change the way in
which the NCSP is delivered [44]. For example, commis-
sioning of sexual health services by local authorities is
proposed [5], and for the first time integrated data are
available on chlamydia testing and positivity across all
services [45]. These changes offer an opportunity for
closer working between infection control and health
improvement.
Having uncovered the implicit theory, future research
could explicitly address it through examining the provision
of sexual health advice delivered within the Programme,
and by exploring the Programme’s impact on attitudes to
testing and testing behaviour.
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